肝动脉化疗栓塞治疗原发性肝癌临床分析

Hepatic Artery Chemotherapy Embolism Treats the Primary Liver Cancer Clinical Analysis

目的:评价肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效。方法:回顾性分析28例原发性肝癌患者TACE治疗的临床资料。结果:本组28例患者共行TACE治疗55次。治疗后1个月,部分缓解15例,占53.6%;微效6例,占21.4%;稳定4例,占14.3%;进展3例,占10.7%。22例AFP阳性者中,完全恢复正常9例(40.9%);治疗后AFP下降≥50%7例(31.8%),AFP下降<50%5例(22.7%),AFP升高者1例(4.5%)。AFP总下降率为95.5%。TACE后出现不同程度的发热、白细胞减低、胃肠道反应、肝区疼痛和血清转氨酶升高。经对症处理症状大多在1～2周内缓解,不影响治疗。结论:TACE治疗方法减轻了患者痛苦,可延长患者生存时间,为非外科手术切除治疗的首选方法之一,值得临床推广。

Objective： To evaluate the clinical efficacy of hepatic arterial chemoembolization （TACE） for hepatocellular carcinoma. Methods：The clinical data of 28 cases of patients with primary liver cancer by the TACE treatment were retrospectively analyzed. Results：28 cases of patients in this group with a total of 55 times of TACE treatment. 1 month after treatment, 15 cases of partial remission, accounting for 53.6%; 6 cases of minor, accounting for 21.4%; four cases of stable, accounting for 14.3%; three cases of the progress, accounting for 10.7%. Among 22 cases of AFP-positive patients, 9 cases completely back to normal（40.9%）; AFP of 7 cases declined 〉50% after treatment （31.8%）, 5 cases of AFP decreased 〈50% （22.7%）, 1 case of AFP elevated （4.5%）. The total rate of AFP decline was 95.5 percent. After TACE, there were varying degrees of fever, leukocyte reduction, gastrointestinal reactions, liver pain and elevated serum transaminase. Symptoms mostly eased in the 1-2 weeks after symptomatic treatment, did not affect the treatment. Conclusion：TACE can alleviate patient suffering, extend survival time of patients, is one of the preferred methods of treatment of non-surgical removal,worthy to be popularized.